Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Abbvie Inc’s stock clocked out at $179.84, up 2.37% from its previous closing price of $175.67. In other words, the price has increased by $2.37 from its previous closing price. On the day, 18.83 million shares were traded. ABBV stock price reached its highest trading level at $180.29 during the session, while it also had its lowest trading level at $164.39.
Ratios:
To gain a deeper understanding of ABBV’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 57.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.84. For the most recent quarter (mrq), Quick Ratio is recorded 0.55 and its Current Ratio is at 0.66. In the meantime, Its Debt-to-Equity ratio is 20.40 whereas as Long-Term Debt/Eq ratio is at 18.36.
On December 05, 2024, Daiwa Securities Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $180.
Leerink Partners Upgraded its Market Perform to Outperform on November 22, 2024, while the target price for the stock was maintained at $206.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 31 ’25 when Stewart Jeffrey Ryan sold 58,832 shares for $210.08 per share. The transaction valued at 12,359,504 led to the insider holds 53,234 shares of the business.
Stewart Jeffrey Ryan bought 58,832 shares of ABBV for $12,359,897 on Mar 31 ’25. On Mar 14 ’25, another insider, Reents Scott T, who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 17,644 shares for $212.34 each. As a result, the insider received 3,746,527 and left with 11,577 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 318133338112 and an Enterprise Value of 392553758720. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 75.20, and their Forward P/E ratio for the next fiscal year is 12.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.93. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.65 while its Price-to-Book (P/B) ratio in mrq is 95.48. Its current Enterprise Value per Revenue stands at 6.968 whereas that against EBITDA is 14.692.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.64, which has changed by 0.07354343 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $218.66, while it has fallen to a 52-week low of $153.58. The 50-Day Moving Average of the stock is -10.34%, while the 200-Day Moving Average is calculated to be -4.27%.
Shares Statistics:
It appears that ABBV traded 6.93M shares on average per day over the past three months and 10485490 shares per day over the past ten days. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.11% of the company’s shares, while institutions hold 73.43% stake in the company. Shares short for ABBV as of 1741910400 were 19695617 with a Short Ratio of 2.84, compared to 1739491200 on 19623497. Therefore, it implies a Short% of Shares Outstanding of 19695617 and a Short% of Float of 1.11.
Dividends & Splits
With its trailing 12-month dividend rate of 6.29, ABBV has a forward annual dividend rate of 6.29. Against a Trailing Annual Dividend Yield of 0.035805773The stock’s 5-year Average Dividend Yield is 3.99.
